BPC 157

BPC-157 (Pentadecapeptide) by Dragon Pharma

BPC-157 is Dragon Pharma's formulation of the pentadecapeptide BPC-157 at 2mg per vial — a 15 amino acid peptide derived from a protective protein found in gastric juice, widely used for its localised tissue-healing properties. Supplied as a lyophilised vial requiring reconstitution, BPC-157 is dosed via subcutaneous injection, often near the site of injury.

Also searched as: BPC 157 peptide, pentadecapeptide BPC-157, BPC-157 2mg vial, BPC 157 Dragon Pharma.

What Is BPC-157?

BPC-157 (Body Protecting Compound 157) is a synthetic pentadecapeptide — a stable fragment derived from a larger protective protein naturally present in gastric juice. Its name reflects its origin: research into gastric protection led to the discovery of its broader tissue-healing properties across tendons, ligaments, muscle and the gastrointestinal tract. Unlike systemic recovery peptides, BPC-157 is most effective when administered near the specific site requiring repair, making injection location a meaningful part of how it's used.

Effects and Benefits

• Localised healing support for tendons, ligaments and muscle tissue when injected near the injury site
• Support for gastrointestinal tissue, reflecting its origin as a gastric-protective compound
• Commonly used for joint-related discomfort, particularly during periods of increased training load
• No suppression of natural testosterone — does not require Post Cycle Therapy
• Favourable safety profile with minimal reported side effects in available research

Dosage and Administration

For localised injuries — a specific joint, tendon or muscle — subcutaneous injection near the affected area is the typical approach. For more general recovery support without a specific target area, injection site location is less critical. BPC-157's short half-life (~4 hours) means once or twice daily dosing is standard, often continued over several weeks for an injury-focused protocol.

Side Effects

BPC-157 has a favourable safety profile with minimal reported side effects:

• Injection site reactions are possible but generally mild
• No impact on testosterone, estrogen or the HPG axis — does not suppress natural hormone production
• No PCT required — can be used during AAS cycles, during PCT, or independently at any time
• As with all peptides, product sourcing and proper reconstitution matter for integrity and consistency